tiprankstipranks
GT Biopharma (GTBP)
NASDAQ:GTBP
Holding GTBP?
Track your performance easily

GT Biopharma (GTBP) Income Statement

218 Followers

GT Biopharma Income Statement

Last quarter (Q3 2024), GT Biopharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, GT Biopharma's net income was $-3.41M. See GT Biopharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 7.59M$ 13.58M$ 21.26M$ 57.52M$ 7.08M$ 11.46M
Operating Income
$ -13.77M$ -13.58M$ -21.26M$ -57.52M$ -6.76M$ -11.46M
Net Non Operating Interest Income Expense
$ 839.00K$ 567.00K$ 284.00K$ -680.00K$ 3.00M$ 2.13M
Other Income Expense
$ 1.59M$ 5.41M$ 89.00K$ -182.00K$ -17.75M$ -20.46M
Pretax Income
$ -8.34M$ -7.60M$ -20.88M$ -58.01M$ 7.67M$ 6.54M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -12.38M$ -7.60M$ -20.88M$ -58.01M$ -28.30M$ 6.54M
Basic EPS
$ -7.48$ -5.64$ -19.80$ -61.80$ -193.50$ -11.39
Diluted EPS
$ -7.48$ -5.64$ -19.80$ -61.80$ -193.50$ -11.39
Basic Average Shares
$ 6.71M$ 1.35M$ 1.06M$ 938.52K$ -76.32K$ 3.39M
Diluted Average Shares
$ 6.71M$ 1.35M$ 1.06M$ 938.52K$ 146.17K$ 3.38K
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 7.59M$ 13.58M$ 21.26M$ 57.52M$ 7.08M$ 11.46M
Net Income From Continuing And Discontinued Operation
$ -12.38M$ -7.60M$ -20.88M$ -58.01M$ -28.30M$ 6.54M
Normalized Income
$ -9.80M$ -6.43M-$ -45.83M--
Interest Expense
------
EBIT
$ -7.82M$ -7.38M$ -20.88M$ -57.30M$ -24.98M$ 4.41M
EBITDA
$ -7.76M$ -7.38M$ -20.88M$ -57.30M$ -24.98M$ 4.92M
Currency in USD

GT Biopharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis